MASLD Associated With Substantial Economic Burden Among Patients With T2D
Key Takeaways:
- In a retrospective cohort study examining patients with type 2 diabetes (T2D), the presence of metabolic dysfunction-associated steatotic liver disease (MASLD) was associated with 62% higher all-cause total care costs.
- Among patients with MASLD, those receiving glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors incurred higher costs compared to other medication subgroups.
- Inpatient hospitalizations had the highest spending and utilization rates, highlighting the significance of proper disease management and early intervention.
MASLD is a common comorbidity among patients with T2D. The presence of both conditions is associated with an increased risk of cardiovascular and chronic kidney disease, as well as substantial health care spending and utilization.
Researchers conducted a retrospective cohort study to characterize direct health care utilization and costs associated with MASLD among adults with T2D. These findings are intended to inform payers, policymakers, and providers on intervention strategies to reduce the disease's economic burden.
Economic Burden of MASLD Underscores Need for Early Intervention
The study used administrative claims between January 2016 and June 2025 from the IQVIA PharMetrics Plus Closed Health Plan database. Patients with T2D aged between 18 and 64 were included and categorized into 2 cohorts: those with MASLD and those without.
The primary outcome was all-cause total direct health care costs after 12 months of follow-up. Secondary outcomes included health care utilization costs based on setting: inpatient, outpatient, emergency department (ED), and prescription drug costs.
Patient Characteristics
The final sample size included 155 172 patients with T2D, of whom 17 412 (11.2%) had MASLD and 137 760 (88.8%) did not have MASLD.
Before propensity score matching, younger, female patients with increased comorbidity were more likely to have both MASLD and T2D. After matching, 17 412 pairs were retained with similar baseline covariates.
Health Care Utilization and Costs Associated With MASLD
The average all-cause total costs after 12 months were $29 734 among patients with MASLD and $18 320 among matched controls. After adjustments, patients with MASLD had 62% higher total care costs, resulting in an average marginal effect (AME) of $11 411 per patient per year.
Patients with MASLD had higher care costs across all settings, with inpatient hospitalizations accumulating the greatest spending with an AME of $4473. AMEs for outpatient, prescription drug costs, and ED were $3699, $2965, and $297, respectively.
When analyzed by medication subgroup, costs were highest among those receiving SGLT2 inhibitors (AME: $13 842) and GLP-1 RAs (AME: $10 653).
Corresponding to increased costs, MASLD was associated with increased health care utilization as well. Compared to those without, patients with MASLD had more hospitalizations (2.10 vs 1.18), outpatient visits (17.18 vs 12.81), and ED visits (1.05 vs 0.55).
Implications for Managed Care
These findings characterize the substantial economic burden associated with MASLD, with significant increases in care costs and utilization compared to those without MASLD.
Costs and utilization were highest in inpatient settings, indicating the importance of enhanced disease management and early intervention strategies to slow disease progression.
Reference
Tran TH, Kim H, McCoy RG, Zafari Z. Real-world cost and utilisation burden of diagnosed metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes in the United States: a retrospective cohort study. Diabetes Obes Metab. 2026;28(12): 11394-11406. doi:10.1111/dom.71355


